Blog
Blog
Navigating the Post-COVID Hangover for Life Sciences Markets
Navigating the Post-COVID Hangover for Life Sciences Markets By: Paul Mieyal, PhD, CFA Over the past several years, we saw the reemergence of the TINA...
Read MoreBlog
Outcome MedTech Market Movers: Boston Scientific – Corporate Update
While many in the medtech industry are struggling, BSX’s strategic M&A is enabling continued growth and market share expansion, with cardiology segment driving key growth and revenue contribution.
Read MoreBlog
Outcome Biotech Market Movers: Wide-Ranging Late-Stage Pipeline Propels Ionis Pharmaceutical, Inc.
Leveraging differentiated therapeutic platforms, biotech companies leverage comprehensive product pipeline across various indications, attracting multiple strategic partnerships to enable rapid growth.
Read MoreBlog
Outcome MedTech Market Movers: COVID Concern Diminishing, CooperCompanies Exceeds Q1/22 Guidance, M&A Strategy Energizing Returns
M&A and Tuck in acquisitions continue to provide inorganic growth opportunities for medtech players seeking to leverage current footprint and fast track product offerings.
Read MoreBlog
Outcome MedTech Market Movers: Amid Pandemic Headwinds, Strategic Positioning & Innovative Technology Drive Growth Outlook
Leading MedTech strategic players are aggressively seeking tuck-in opportunities in the post-Covid era to strengthen existing business units, with waning market sentiment presents unique timing for M&A as companies seek to deploy cash.
Read MoreBlog
I am a Scientist-Banker at Outcome Capital
Dr. John Armstrong, Managing Director in Outcome Capital’s biotech practice, explains why he chose investment banking for the next phase of his career, and why he chose Outcome Capital, specifically.
Read MoreBlog
Pioneers Give Us Hope
Pioneers give us hope. At Outcome Capital, we thrive on supporting pioneers in the life sciences. You are what we live for. We help you get financed, partnered, and acquired. We are the ones working to ensure that the trails you blaze bring the rest of the world into the light.
Read MoreBlog
The Accelerated Maturation Of Digital Health: Thoughts From HLTH 2021
Navigating the hyper growth of the digital sector presents a challenge to management teams in navigating a de-differentiated and highly competitive environment.
Read MoreBlog
Raising capital is Not a Numbers Game
The secret to successfully raising capital is strategy – strategic positioning, targeting, and timing. Outcome Capital deploys strategy to get it right the first time so you don’t hurt your chances for the future.
Read MoreBlog
Life Science Entrepreneurs: Embrace the Risks
Our strategic advice is based on data and on market-driven feedback. We want you to win, and if you have a coachable persona, we know that you will be open to professional strategic guidance toward maximizing your chances of reaching a liquidity event, whether that an M&A, strategic partnership, or equity financing transaction.
Read MoreBlog
Winning Matters
At Outcome Capital, getting you to exit and getting your technology to patients matters to us. When we engage, we don’t go to participate; we don’t go to try hard; we go to win, because winning matters.
Read MoreBlog
Bringing Polymath Power to Biotech Banking
Success in identifying strategic partnerships and transacting M&As deal in the knowledge-intensive and highly complex Biotech industry requires a multi-disciplinary approach from investment banking firms. The scientist-bankers at Boston-based Outcome Capital define a step-up from the ordinary.
Read MoreBlog
Caught By Surprise: The Diagnostic Industry in The Time of COVID
World markets are looking to the diagnostic industry to rapidly diagnose and monitor the COVID -19 pandemic but the segment received limited venture support over the past several years. The COVID-19 crisis has shown that pandemics are real, their impacts on health and the economy are devastating, and it is through renewed innovation that we find relief.
Read MoreBlog
Tainting the Market: Why Early & Widespread Market Outreach Can Hurt
As a specialized life science advisory and investment banking group, Outcome Capital is often in the unique position to see companies who have gone to market prematurely and consequently have been unsuccessful in either raising capital or seeking an acquisition partner. What management often does not realize is that the failure of these first-time efforts can leave the market with a tainted impression of their company
Read MoreBlog
Outcome’s Digital Health Practice Takeaways from MassBio’s Life Science Entrepreneurs Impact Summit
As the digital health segment is rapidly gaining momentum, entrepreneurs are advised to focus on technologies that clearly demonstrate improved clinical outcomes, or quickly and capital-efficiently integrate into hospital workflows toward reduce cost reduction.
Read MoreBlog
Board Dysfunction and the CEO
Boards should consist of two key stakeholders: Investors, who have the financial ability to support the company and industry experts, who could provide domain expertise, external perspective, as well as a deep network.
Read MoreBlog
Top Five Recurring Mistakes (And Remedies) In Life Science M&A
Given that M&A transactions are pivotal in moving innovation from the laboratory to the patient, it is imperative that management teams understand that the selling of a company is an arduous, time-consuming, and a high-risk process. As members of a specialized life sciences investment banking group focused on private equity financing and M&A, we often note that life science management teams fall victim to recurring mistakes and entrapments. Below is a list of avoidable missteps in M&A transactions and their respective remedies:
Read MoreBlog
Pitching Your Company: On the Importance of Seeking Dialogue and Avoiding Monologue
The idea of CEOs “pitching” their company evokes images of detailed PowerPoint presentations and exuberant speeches. While intricate presentations given with dramatic flare might seem like an appealing route for entrepreneurs to take, seasoned CEOs leverage the opportunity to discuss their company, form relationships and receive invaluable feedback.
Read MoreBlog
Pitching Your Company: Key Distinctions to Make When Meeting With Potential Investors or Acquirers
Whether in the early stages of attracting capital, or engaging in discussions with strategic acquirers, successful life science management teams are careful to make important distinctions when “pitching” their company. Below, are topics that are occasionally confused to the detriment of otherwise marketable technologies and companies.
Read MoreBlog
The Liquid Biopsy Segment Is Coming Into Its Own
Beginning with Roche’s acquisition of the balance of Foundation Medicine for $2.4 billion this past June, the long championed (yet unrealized) promise of the liquid biopsy market has begun to take shape. Investments and acquisitions in the space are undoubtedly only just beginning, and we look forward to seeing this market continue to mature and grow.
Read MoreContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
